Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home

Delisted Patents

About This List

The following is a list of patents that have been delisted since the most recent Annual Edition of the Orange Book.

Additional Information about Patents
  • Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
  • Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
  • As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

The following is a list of patents that have been delisted since the most recent Annual Edition of the Orange Book.

Appl No Active Ingredient Proprietary Name Dosage
Form
Route Strength Patent No. Patent Use Mkt. Status Submission Date
Appl No Active Ingredient Proprietary Name Dosage
Form
Route Strength Patent No. Patent Use Mkt. Status Submission Date
N020800 EPINEPHRINE ADRENACLICK INJECTABLE INTRAMUSCULAR, SUBCUTANEOUS EQ 0.15MG/DELIVERY 10166344
RX 11/15/2019
N020800 EPINEPHRINE ADRENACLICK INJECTABLE INTRAMUSCULAR, SUBCUTANEOUS EQ 0.3MG/DELIVERY 10166344
RX 11/15/2019
N204629 EMPAGLIFLOZIN JARDIANCE TABLET ORAL 25MG 10406172
U-1652 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
RX 09/30/2019
N204629 EMPAGLIFLOZIN JARDIANCE TABLET ORAL 10MG 10406172
U-1652 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
RX 09/30/2019
N206073 EMPAGLIFLOZIN; LINAGLIPTIN GLYXAMBI TABLET ORAL 25MG;5MG 10406172
U-1652 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
RX 09/30/2019
N206073 EMPAGLIFLOZIN; LINAGLIPTIN GLYXAMBI TABLET ORAL 10MG;5MG 10406172
U-1652 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
RX 09/30/2019
N021361 RIFAXIMIN XIFAXAN TABLET ORAL 200MG 10709694
U-2579 REDUCTION IN A SUBJECT'S RISK OF EXPERIENCING A BREAKTHROUGH OVERT HEPATIC ENCEPHALOPATHY (HE) EPISODE
RX 07/23/2020
N202450 ACLIDINIUM BROMIDE TUDORZA PRESSAIR POWDER, METERED INHALATION 0.4MG/INH 6750226
U-1264 TREATMENT OF A RESPIRATORY DISEASE
RX 08/17/2012
N021286 OLMESARTAN MEDOXOMIL BENICAR TABLET ORAL 5MG 6878703
U-3 TREATMENT OF HYPERTENSION
RX
N021286 OLMESARTAN MEDOXOMIL BENICAR TABLET ORAL 20MG 6878703
U-3 TREATMENT OF HYPERTENSION
RX
N021286 OLMESARTAN MEDOXOMIL BENICAR TABLET ORAL 40MG 6878703
U-3 TREATMENT OF HYPERTENSION
RX
N021532 HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL BENICAR HCT TABLET ORAL 12.5MG;20MG 6878703
U-3 TREATMENT OF HYPERTENSION
RX
N021532 HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL BENICAR HCT TABLET ORAL 12.5MG;40MG 6878703
U-3 TREATMENT OF HYPERTENSION
RX
N021532 HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL BENICAR HCT TABLET ORAL 25MG;40MG 6878703
U-3 TREATMENT OF HYPERTENSION
RX
N021286 OLMESARTAN MEDOXOMIL BENICAR TABLET ORAL 5MG 6878703*PED
RX
N021286 OLMESARTAN MEDOXOMIL BENICAR TABLET ORAL 20MG 6878703*PED
RX
N021286 OLMESARTAN MEDOXOMIL BENICAR TABLET ORAL 40MG 6878703*PED
RX
N021532 HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL BENICAR HCT TABLET ORAL 12.5MG;20MG 6878703*PED
RX
N021532 HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL BENICAR HCT TABLET ORAL 12.5MG;40MG 6878703*PED
RX
N021532 HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL BENICAR HCT TABLET ORAL 25MG;40MG 6878703*PED
RX
N021251 LOPINAVIR; RITONAVIR KALETRA SOLUTION ORAL 80MG/ML;20MG/ML 6911214
U-895 TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
RX
N021251 LOPINAVIR; RITONAVIR KALETRA SOLUTION ORAL 80MG/ML;20MG/ML 6911214*PED
RX
N020945 RITONAVIR NORVIR CAPSULE ORAL 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** 7141593
DISCN
N021226 LOPINAVIR; RITONAVIR KALETRA CAPSULE ORAL 133.3MG;33.3MG 7141593
DISCN
N020945 RITONAVIR NORVIR CAPSULE ORAL 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** 7141593*PED
DISCN
N021226 LOPINAVIR; RITONAVIR KALETRA CAPSULE ORAL 133.3MG;33.3MG 7141593*PED
DISCN
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 200MG;50MG 7148359
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 100MG;25MG 7148359
RX
N022417 RITONAVIR NORVIR TABLET ORAL 100MG 7148359
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 200MG;50MG 7148359*PED
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 100MG;25MG 7148359*PED
RX
N022417 RITONAVIR NORVIR TABLET ORAL 100MG 7148359*PED
RX
N209939 LETERMOVIR PREVYMIS TABLET ORAL 240MG 7196086
RX 12/07/2017
N209939 LETERMOVIR PREVYMIS TABLET ORAL 480MG 7196086
RX 12/07/2017
N209940 LETERMOVIR PREVYMIS SOLUTION INTRAVENOUS 240MG/12ML (20MG/ML) 7196086
RX 12/07/2017
N209940 LETERMOVIR PREVYMIS SOLUTION INTRAVENOUS 480MG/24ML (20MG/ML) 7196086
RX 12/07/2017
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 200MG;50MG 7364752
U-688 TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 100MG;25MG 7364752
U-688 TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
RX
N022417 RITONAVIR NORVIR TABLET ORAL 100MG 7364752
U-688 TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 200MG;50MG 7364752*PED
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 100MG;25MG 7364752*PED
RX
N022417 RITONAVIR NORVIR TABLET ORAL 100MG 7364752*PED
RX
N020945 RITONAVIR NORVIR CAPSULE ORAL 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** 7432294
DISCN
N021226 LOPINAVIR; RITONAVIR KALETRA CAPSULE ORAL 133.3MG;33.3MG 7432294
DISCN
N020945 RITONAVIR NORVIR CAPSULE ORAL 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** 7432294*PED
DISCN
N021226 LOPINAVIR; RITONAVIR KALETRA CAPSULE ORAL 133.3MG;33.3MG 7432294*PED
DISCN
N205777 NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE TARGINIQ TABLET, EXTENDED RELEASE ORAL 10MG;20MG 7674799
DISCN 07/29/2014
N205777 NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE TARGINIQ TABLET, EXTENDED RELEASE ORAL 5MG;10MG 7674799
DISCN 07/29/2014
N205777 NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE TARGINIQ TABLET, EXTENDED RELEASE ORAL 20MG;40MG 7674799
DISCN 07/29/2014
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 30MG 7674799
RX
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 60MG 7674799
RX
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 80MG 7674799
RX
N205777 NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE TARGINIQ TABLET, EXTENDED RELEASE ORAL 10MG;20MG 7674800
DISCN 07/29/2014
N205777 NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE TARGINIQ TABLET, EXTENDED RELEASE ORAL 5MG;10MG 7674800
DISCN 07/29/2014
N205777 NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE TARGINIQ TABLET, EXTENDED RELEASE ORAL 20MG;40MG 7674800
DISCN 07/29/2014
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 30MG 7674800
RX
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 60MG 7674800
RX
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 80MG 7674800
RX
N205777 NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE TARGINIQ TABLET, EXTENDED RELEASE ORAL 10MG;20MG 7683072
DISCN 07/29/2014
N205777 NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE TARGINIQ TABLET, EXTENDED RELEASE ORAL 5MG;10MG 7683072
DISCN 07/29/2014
N205777 NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE TARGINIQ TABLET, EXTENDED RELEASE ORAL 20MG;40MG 7683072
DISCN 07/29/2014
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 30MG 7683072
RX
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 60MG 7683072
RX
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 80MG 7683072
RX
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 80MG 7776314
RX
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 30MG 7776314
RX
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 60MG 7776314
RX
N207981 TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE LONSURF TABLET ORAL EQ 8.19MG BASE;20MG 7799783
U-1751 TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY
RX 10/13/2015
N207981 TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE LONSURF TABLET ORAL EQ 6.14MG BASE;15MG 7799783
U-1751 TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY
RX 10/13/2015
N022200 EXENATIDE SYNTHETIC BYDUREON FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 2MG/VIAL 7851502
RX 11/17/2017
N022200 EXENATIDE SYNTHETIC BYDUREON PEN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 2MG 7851502
RX 11/15/2017
N022200 EXENATIDE SYNTHETIC BYDUREON FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 2MG/VIAL 7919598
RX 11/17/2017
N022200 EXENATIDE SYNTHETIC BYDUREON PEN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 2MG 7919598
RX 11/15/2017
N205832 NINTEDANIB ESYLATE OFEV CAPSULE ORAL EQ 150MG BASE 7989474
U-1677 TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)
RX 04/13/2015
N205832 NINTEDANIB ESYLATE OFEV CAPSULE ORAL EQ 100MG BASE 7989474
U-1677 TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)
RX 04/13/2015
N022250 DALFAMPRIDINE AMPYRA TABLET, EXTENDED RELEASE ORAL 10MG 8007826
U-1030 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
RX 09/28/2011
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 200MG;50MG 8025899
RX 10/11/2011
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 100MG;25MG 8025899
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 200MG;50MG 8025899*PED
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 100MG;25MG 8025899*PED
RX
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 10MG 8114383
RX 02/14/2012
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 15MG 8114383
RX
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 20MG 8114383
RX
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 30MG 8114383
RX
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 40MG 8114383
RX
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 60MG 8114383
RX 06/26/2012
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 80MG 8114383
RX 06/26/2012
N022200 EXENATIDE SYNTHETIC BYDUREON FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 2MG/VIAL 8221786
RX 11/17/2017
N022200 EXENATIDE SYNTHETIC BYDUREON PEN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 2MG 8221786
RX 11/15/2017
N020622 GLATIRAMER ACETATE COPAXONE INJECTABLE SUBCUTANEOUS 40MG/ML 8232250
U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
RX 02/26/2014
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 200MG;50MG 8268349
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 100MG;25MG 8268349
RX
N022417 RITONAVIR NORVIR TABLET ORAL 100MG 8268349
RX 09/26/2012
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 200MG;50MG 8268349*PED
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 100MG;25MG 8268349*PED
RX
N022417 RITONAVIR NORVIR TABLET ORAL 100MG 8268349*PED
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 200MG;50MG 8309613
U-688 TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
RX 12/05/2012
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 100MG;25MG 8309613
U-688 TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 200MG;50MG 8309613*PED
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 100MG;25MG 8309613*PED
RX
N022250 DALFAMPRIDINE AMPYRA TABLET, EXTENDED RELEASE ORAL 10MG 8354437
U-1030 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
RX 02/13/2013
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 200MG;50MG 8377952
U-1372 ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION
RX 03/18/2013
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 100MG;25MG 8377952
U-1372 ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 200MG;50MG 8377952*PED
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 100MG;25MG 8377952*PED
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 200MG;50MG 8399015
RX 04/05/2013
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 100MG;25MG 8399015
RX
N022417 RITONAVIR NORVIR TABLET ORAL 100MG 8399015
RX 04/08/2013
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 200MG;50MG 8399015*PED
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 100MG;25MG 8399015*PED
RX
N022417 RITONAVIR NORVIR TABLET ORAL 100MG 8399015*PED
RX
N020622 GLATIRAMER ACETATE COPAXONE INJECTABLE SUBCUTANEOUS 40MG/ML 8399413
U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
RX 02/26/2014
N022250 DALFAMPRIDINE AMPYRA TABLET, EXTENDED RELEASE ORAL 10MG 8440703
U-1030 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
RX 06/12/2013
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 200MG;50MG 8470347
RX 07/12/2013
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 100MG;25MG 8470347
RX
N022417 RITONAVIR NORVIR TABLET ORAL 100MG 8470347
RX 07/12/2013
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 200MG;50MG 8470347*PED
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 100MG;25MG 8470347*PED
RX
N022417 RITONAVIR NORVIR TABLET ORAL 100MG 8470347*PED
RX
N021251 LOPINAVIR; RITONAVIR KALETRA SOLUTION ORAL 80MG/ML;20MG/ML 8501219
RX 08/26/2013
N021372 PALONOSETRON HYDROCHLORIDE ALOXI INJECTABLE INTRAVENOUS EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) 8598219
RX
N021372 PALONOSETRON HYDROCHLORIDE ALOXI INJECTABLE INTRAVENOUS EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) 8598219*PED
RX
N206406 TACROLIMUS ENVARSUS XR TABLET, EXTENDED RELEASE ORAL EQ 0.75MG BASE 8644239
U-2678 PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT
RX 12/20/2019
N206406 TACROLIMUS ENVARSUS XR TABLET, EXTENDED RELEASE ORAL EQ 0.75MG BASE 8644239
U-2677 PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS
RX 12/20/2019
N206406 TACROLIMUS ENVARSUS XR TABLET, EXTENDED RELEASE ORAL EQ 4MG BASE 8644239
U-2678 PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT
RX 12/20/2019
N206406 TACROLIMUS ENVARSUS XR TABLET, EXTENDED RELEASE ORAL EQ 4MG BASE 8644239
U-2677 PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS
RX 12/20/2019
N206406 TACROLIMUS ENVARSUS XR TABLET, EXTENDED RELEASE ORAL EQ 1MG BASE 8644239
U-2678 PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT
RX 12/20/2019
N206406 TACROLIMUS ENVARSUS XR TABLET, EXTENDED RELEASE ORAL EQ 1MG BASE 8644239
U-2677 PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS
RX 12/20/2019
N212614 EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE TRIJARDY XR TABLET, EXTENDED RELEASE ORAL 12.5MG;2.5MG;1GM 8673927
U-1652 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
RX 02/18/2020
N212614 EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE TRIJARDY XR TABLET, EXTENDED RELEASE ORAL 25MG;5MG;1GM 8673927
U-1652 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
RX 02/18/2020
N212614 EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE TRIJARDY XR TABLET, EXTENDED RELEASE ORAL 10MG;5MG;1GM 8673927
U-1652 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
RX 02/18/2020
N212614 EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE TRIJARDY XR TABLET, EXTENDED RELEASE ORAL 5MG;2.5MG;1GM 8673927
U-1652 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
RX 02/18/2020
N022200 EXENATIDE SYNTHETIC BYDUREON FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 2MG/VIAL 8685934
U-1522 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
RX 11/17/2017
N022200 EXENATIDE SYNTHETIC BYDUREON PEN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 2MG 8685934
U-1522 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
RX 11/15/2017
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 200MG;50MG 8691878
U-1513 TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
RX 06/10/2014
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 100MG;25MG 8691878
U-1513 TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
RX 06/10/2014
N022417 RITONAVIR NORVIR TABLET ORAL 100MG 8691878
U-688 TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
RX 06/10/2014
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 200MG;50MG 8691878*PED
RX
N021906 LOPINAVIR; RITONAVIR KALETRA TABLET ORAL 100MG;25MG 8691878*PED
RX
N022417 RITONAVIR NORVIR TABLET ORAL 100MG 8691878*PED
RX
N022200 EXENATIDE SYNTHETIC BYDUREON FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 2MG/VIAL 8716251
RX 11/17/2017
N022200 EXENATIDE SYNTHETIC BYDUREON PEN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 2MG 8716251
RX 11/15/2017
N020622 GLATIRAMER ACETATE COPAXONE INJECTABLE SUBCUTANEOUS 40MG/ML 8969302
U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
RX 03/03/2015
N022272 OXYCODONE HYDROCHLORIDE OXYCONTIN TABLET, EXTENDED RELEASE ORAL 10MG 9060976
RX 06/23/2015
N020622 GLATIRAMER ACETATE COPAXONE INJECTABLE SUBCUTANEOUS 40MG/ML 9155776
U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
RX 10/13/2015
N201280 LINAGLIPTIN TRADJENTA TABLET ORAL 5MG 9173859
U-1768 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN
RX 11/19/2015
N201280 LINAGLIPTIN TRADJENTA TABLET ORAL 5MG 9173859
U-1503 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
RX 11/19/2015
N201281 LINAGLIPTIN; METFORMIN HYDROCHLORIDE JENTADUETO TABLET ORAL 2.5MG;500MG 9173859
U-1503 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
RX 11/19/2015
N201281 LINAGLIPTIN; METFORMIN HYDROCHLORIDE JENTADUETO TABLET ORAL 2.5MG;850MG 9173859
U-1503 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
RX 11/19/2015
N201281 LINAGLIPTIN; METFORMIN HYDROCHLORIDE JENTADUETO TABLET ORAL 2.5MG;1GM 9173859
U-1503 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
RX 11/19/2015
N212614 EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE TRIJARDY XR TABLET, EXTENDED RELEASE ORAL 12.5MG;2.5MG;1GM 9173859
U-1652 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
RX 02/18/2020
N212614 EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE TRIJARDY XR TABLET, EXTENDED RELEASE ORAL 12.5MG;2.5MG;1GM 9173859
U-2730 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
RX 02/18/2020
N212614 EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE TRIJARDY XR TABLET, EXTENDED RELEASE ORAL 25MG;5MG;1GM 9173859
U-1652 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
RX 02/18/2020
N212614 EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE TRIJARDY XR TABLET, EXTENDED RELEASE ORAL 25MG;5MG;1GM 9173859
U-2730 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
RX 02/18/2020
N212614 EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE TRIJARDY XR TABLET, EXTENDED RELEASE ORAL 10MG;5MG;1GM 9173859
U-1652 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
RX 02/18/2020
N212614 EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE TRIJARDY XR TABLET, EXTENDED RELEASE ORAL 10MG;5MG;1GM 9173859
U-2730 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
RX 02/18/2020
N212614 EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE TRIJARDY XR TABLET, EXTENDED RELEASE ORAL 5MG;2.5MG;1GM 9173859
U-1652 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
RX 02/18/2020
N212614 EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE TRIJARDY XR TABLET, EXTENDED RELEASE ORAL 5MG;2.5MG;1GM 9173859
U-2730 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
RX 02/18/2020
N020622 GLATIRAMER ACETATE COPAXONE INJECTABLE SUBCUTANEOUS 40MG/ML 9402874
U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
RX 08/02/2016
N207202 ARIPIPRAZOLE ABILIFY MYCITE KIT TABLET ORAL 10MG 9577864
U-2169 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
RX 12/12/2017
N207202 ARIPIPRAZOLE ABILIFY MYCITE KIT TABLET ORAL 5MG 9577864
U-2169 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
RX 12/12/2017
N207202 ARIPIPRAZOLE ABILIFY MYCITE KIT TABLET ORAL 30MG 9577864
U-2169 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
RX 12/12/2017
N207202 ARIPIPRAZOLE ABILIFY MYCITE KIT TABLET ORAL 15MG 9577864
U-2169 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
RX 12/12/2017
N207202 ARIPIPRAZOLE ABILIFY MYCITE KIT TABLET ORAL 2MG 9577864
U-2169 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
RX 12/12/2017
N207202 ARIPIPRAZOLE ABILIFY MYCITE KIT TABLET ORAL 20MG 9577864
U-2169 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
RX 12/12/2017

View a list of all patent use codes
View a list of all exclusivity codes

Last Updated September 18, 2020.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English